Cite
HARVARD Citation
Sandborn, W. et al. (n.d.). O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα. Inflammatory bowel diseases. p. . [Online].